ColorectalArchives
Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial
Colorectal 5 min.
Colorectal cancer (CRC) is the third most common cancer and the second most deadly cancer worldwide [1]. In China, colorectal cancer ranks as the fourth most common malignancy and accounted for approximately 240,000 deaths in 2022 [2]. In recent years, systemic chemotherapy combined with targeted therapy...
Comparative analysis of osteoporotic versus pathologic fracture in metastatic colorectal cancer patients
Colorectal 5 min.
Colorectal cancer (CRC) is the third most prevalent malignancy worldwide [1]. Although the prognosis of patients with metastatic CRC (mCRC) is generally poor, recent developments in novel chemotherapeutic agents have increased the overall survival of patients to approximately 30 months [2]. In line with...
COMP promotes the progression of colorectal cancer by regulating epithelial mesenchymal transition
Colorectal 7 min.
Colorectal cancer (CRC) is one of the most common malignant tumors worldwide, with increasing incidence and mortality rates each year [1, 2]. Its clinical characteristics mainly include locally invasive growth and distant metastasis [3]. Despite advances in surgical techniques, chemotherapy, and radiotherapy,...
Clinical and epidemiological profile of patients with colorectal cancer in Bhutan: a cross-sectional study
Colorectal 4 min.
Colorectal cancer is the third most common malignancy and the third leading cause of cancer-related deaths worldwide [1]. Globally, the burden of colorectal cancer cases has more than doubled, from 0.84 million to 2.17 million, and deaths increased from 0.51 million to 1.09 million...
